- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01233778
Canola Oil Multicentre Intervention Trial (COMIT) (COMIT)
Canola and Flax Oils in Modulation of Vascular Function and Biomarkers of Cardiovascular Disease Risk
Study Overview
Status
Conditions
Detailed Description
The consequence of total fat consumption on circulating plasma lipids and the incidence of cardiovascular disease has long been a central theme in nutrition research. Less well known is the influence of specific fatty acids on vascular endothelial function and the oxidative and inflammatory responses characteristic of atherogenesis. Omega 3 ( ω-3) fatty acids, including plant derived alpha-linolenic acid (18:3n-3, ALA) and marine derived eicosapentaenoic (20:5n-3, EPA) and docosahexaenoic acid (22:6n-3, DHA) have been shown to effectively modulate multiple cardiovascular risk factors in epidemiological, animal model and human clinical investigations. ALA is most commonly consumed as a major component of dietary canola and flaxseed oils and has a recommended intake of 1.1 and 1.6 g/d for women and men, respectively. EPA and DHA are consumed as fatty fish or fish oil and algae supplements with current recommended intakes of 500 mg/d (combined EPA and DHA).
ALA is thought to improve cardiovascular health by modulating circulating lipid concentrations, altering membrane structure and function by enhancing the total ω-3 fatty acid content of cell membrane phospholipids, and reducing inflammatory reactions by blocking the formation of arachidonic acid derived eicosanoids. However, there are extensive knowledge gaps in our understanding of the molecular mechanisms and clinical efficacy of ω-3 fatty acids in human health and disease prevention. Therefore, the purpose of this study is to further examine these relationships.
Feeding protocol and study treatments:
The study will proceed as a double blind, randomized cross-over controlled feeding study. Each treatment phase will be 30 days in duration, separated by 4-week washout periods. Subjects will consume a fixed composition of a precisely controlled basal, weight-maintaining diet (35% energy from fat, 50% carbohydrate, and 15% protein) supplemented with 60g/d of the following treatment oils: 1) canola oil; 2) DHA enriched canola-oil; 3) high oleic acid canola oil; 4) flax/corn oil (40:60); or 5) safflower/corn oil (75:25). Study diets will be prepared in a metabolic kitchen facility at each clinical site. Three isocaloric meals will be prepared each day for every subject. A 7-day rotating menu cycle will be used. Subjects will consume at least 1 of 3 daily meals under supervision. The other meals will be prepared and packed for every subject to be taken out. The study control and intervention oils will be delivered in milkshakes provided twice daily. Subjects will be instructed to consume only the prepared meals and limit their intake of alcohol to 2 drinks/week and caffeinated calorie free beverages to 40oz (5 drinks) per day. Diets will be planned for every subject according to his/her energy requirements and will be nutritionally adequate.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
University Park, Pennsylvania, United States, 16802
- Penn State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 20-65 years
- BMI = 22-32 kg/m2
In addition, eligibility will be based on metabolic syndrome criteria where we define eligibility on the basis of subjects having elevated waist circumference + 1 or more of the remaining 5 criteria:
- Elevated waist circumference - > 102 cm for men and >88 cm for women
- Elevated triglycerides - ≥ 1.7 mmol/L ( ≥150mg/dl) ( no upper limit)
- Reduced HDL - < 1 mmol/L (<40 mg/dl) for men and < 1.3 mmol/L (<50 mg/dl)for women
- Fasting glucose - ≥ 100 mg/dl (no upper limit)
Elevated blood pressure - systolic ≥130 and/or diastolic ≥85 mm HG
- Unmedicated participants - upper limit of Stage 1 Hypertension: systolic ≤ 159 and/or diastolic ≤ 99 mm HG and participants must be free of end stage/target organ disease symptoms
- BP medicated participants: acceptable as long as individuals meet the specified blood pressure range of <140/90 mmHg, and have been stable for at least 6 months.
Exclusion Criteria:
- Smokers**
- History of thyroid disease, diabetes, kidney or liver disease, heart disease, or other chronic diseases
- Heavy alcohol consumption (>14 drinks/week)
- Chronic anti-inflammatory medication use
- Lactation, pregnancy, or desire to become pregnant during the study
- Taking lipid lowering medications (cholestyramine, colestipol, niacin, clofibrate, gemfibrozil probucol, HMG CoA reductase inhibitors) within the last three months
- Not willing to refrain from blood/plasma donation during the study period
Gall bladder removal
- For purposes of the this study non-smoking is defined as >6 months smoke-free; there is some evidence to show that smoking cessation increases HDL levels and 6 months is adequate time for this to stabilize, however this time span was chosen based on the decreased rate of relapse after 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Canola Oil
|
60g Canola oil daily per 3000kcal diet provided in a supplemental shake
|
Experimental: High Oleic Acid Canola + DHA
|
60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
|
Experimental: High Oleic Canola Oil
|
60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
|
Experimental: Flax & Safflower Oil (60:40)
|
36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
|
Experimental: Safflower & Corn Oil (75:25)
|
45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endothelial Health
Time Frame: End of diet period 1 (week 4)
|
Study subjects will undergo endothelial health assessment by EndoPAT analysis.
The EndoPat procedure will occur while the subject is lying down in a relaxed state.
Throughout the study, the inflation pressure of the EndoPAT device will be electronically set to 10mm Hg below diastolic BP.
Testing begins with 10 min of rest.
Following rest, baseline pulse amplitude is measured from each fingertip for 5 min.
Next, arterial flow is interrupted for 5 min by a cuff placed on the forearm at an occlusion pressure of 250 mmHg.
Following occlusion release, pulse amplitude recording continues for 5 min.
|
End of diet period 1 (week 4)
|
Endothelial Health
Time Frame: End of diet period 2 (week 12)
|
Study subjects will undergo endothelial health assessment by EndoPAT analysis.
The EndoPat procedure will occur while the subject is lying down in a relaxed state.
Throughout the study, the inflation pressure of the EndoPAT device will be electronically set to 10mm Hg below diastolic BP.
Testing begins with 10 min of rest.
Following rest, baseline pulse amplitude is measured from each fingertip for 5 min.
Next, arterial flow is interrupted for 5 min by a cuff placed on the forearm at an occlusion pressure of 250 mmHg.
Following occlusion release, pulse amplitude recording continues for 5 min.
|
End of diet period 2 (week 12)
|
Endothelial Health
Time Frame: End of diet period 3 (week 20)
|
Study subjects will undergo endothelial health assessment by EndoPAT analysis.
The EndoPat procedure will occur while the subject is lying down in a relaxed state.
Throughout the study, the inflation pressure of the EndoPAT device will be electronically set to 10mm Hg below diastolic BP.
Testing begins with 10 min of rest.
Following rest, baseline pulse amplitude is measured from each fingertip for 5 min.
Next, arterial flow is interrupted for 5 min by a cuff placed on the forearm at an occlusion pressure of 250 mmHg.
Following occlusion release, pulse amplitude recording continues for 5 min.
|
End of diet period 3 (week 20)
|
Endothelial Health
Time Frame: End of diet period 4 (week 28)
|
Study subjects will undergo endothelial health assessment by EndoPAT analysis.
The EndoPat procedure will occur while the subject is lying down in a relaxed state.
Throughout the study, the inflation pressure of the EndoPAT device will be electronically set to 10mm Hg below diastolic BP.
Testing begins with 10 min of rest.
Following rest, baseline pulse amplitude is measured from each fingertip for 5 min.
Next, arterial flow is interrupted for 5 min by a cuff placed on the forearm at an occlusion pressure of 250 mmHg.
Following occlusion release, pulse amplitude recording continues for 5 min.
|
End of diet period 4 (week 28)
|
Endothelial Health
Time Frame: End of diet period 5 (week 36)
|
Study subjects will undergo endothelial health assessment by EndoPAT analysis.
The EndoPat procedure will occur while the subject is lying down in a relaxed state.
Throughout the study, the inflation pressure of the EndoPAT device will be electronically set to 10mm Hg below diastolic BP.
Testing begins with 10 min of rest.
Following rest, baseline pulse amplitude is measured from each fingertip for 5 min.
Next, arterial flow is interrupted for 5 min by a cuff placed on the forearm at an occlusion pressure of 250 mmHg.
Following occlusion release, pulse amplitude recording continues for 5 min.
|
End of diet period 5 (week 36)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Composition
Time Frame: Week 4, 12, 20, 28 and 36 - End of each diet period
|
To assess regional changes in body fat deposition, subjects will undergo a dual energy X-ray absorptiometry (DXA) scan at baseline (beginning of study) and end of each intervention period.
Waist circumference measurements also will be taken at this time to track how much fat is lost from the abdominal area of the body.
|
Week 4, 12, 20, 28 and 36 - End of each diet period
|
Production of long chain fatty acids
Time Frame: Week 4, 12, 20, 28 and 36 - End of each diet period
|
On the 29th day of each diet phase you will be asked to consume three tablespoons of tagged water (known as deuterium).
The movement of these tagged materials will allow us to assess the quantity of long chain fatty acids (EPA and DHA) that your body is producing in response to your diet.
All of the above tagged materials are non-radioactive, non-toxic, and do not pose any health risk to you.
Another fasting blood sample will be obtained when you return the next morning.
|
Week 4, 12, 20, 28 and 36 - End of each diet period
|
Plasma Lipids
Time Frame: Week 4, 12, 20, 28 and 36 - End of each diet period
|
Twelve-hour fasting blood samples (30ml) will be collected on day 1, 2, 29 and 30 for analyses of plasma lipids.
Blood samples obtained on day 1 and 2 will be used to measure baseline values for study endpoints, whereas blood samples obtained on the two last days will be used to measure final endpoint values.
|
Week 4, 12, 20, 28 and 36 - End of each diet period
|
Plasma Cytokines
Time Frame: Week 4, 12, 20, 28 and 36 - End of each diet period
|
Twelve-hour fasting blood samples (30ml) will be collected on day 1, 2, 29 and 30 for analyses of C-reactive protein and inflammatory cytokines.
Blood samples obtained on day 1 and 2 will be used to measure baseline values for study endpoints, whereas blood samples obtained on the two last days will be used to measure final endpoint values.
|
Week 4, 12, 20, 28 and 36 - End of each diet period
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Penny M Kris-Etherton, PhD, RD, Penn State University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PKE COMIT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on Canola Oil
-
Sarah KeimCures Within Reach; Marci and Bill Ingram Fund for Autism Spectrum Disorders...CompletedPreterm Birth | Child Behavior | Child DevelopmentUnited States
-
University of ManitobaCanola Council of Canada; Alberta Innovates Bio Solutions; Alberta Canola Producers...Completed
-
University of ManitobaUniversity of Toronto; Penn State University; Laval UniversityCompleted
-
Penn State UniversityUniversity of Manitoba; Unity Health Toronto; Laval University; Canola Council... and other collaboratorsCompletedCardiovascular Disease | Metabolic SyndromeUnited States
-
University of ManitobaSt. Boniface HospitalCompletedPeripheral Arterial DiseaseCanada
-
University of ManitobaUniversity of Toronto; University at Buffalo; Penn State University; Agriculture... and other collaboratorsCompletedCardiovascular Disease | Diabetes | Metabolic SyndromeUnited States, Canada
-
Sarah KeimNational Center for Complementary and Integrative Health (NCCIH)CompletedAutism Spectrum DisorderUnited States
-
University of ManitobaCanola Council of Canada; Flax Canada 2015 Inc.; Agri-Food Research and Development...CompletedCardiovascular DiseaseCanada
-
Sarah KeimNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingAutism Spectrum DisorderUnited States
-
Purdue UniversityCompletedAbsorption of Carotenoids From VegetablesUnited States